AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06007690 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Infrared Laser
Description: Sham laser application
Study NCT06007690 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Microinjector
Description: Sham injection device
Study NCT05456360 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: ViSi Mobile device
Description: Participants will wear the device on your wrist like a watch, and it will continuously (non-stop) monitor your pulse, blood pressure, temperature, breathing rate, heart rate, and pulse rate
Study NCT05456360 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Sleep enhancement intervention
Description: Participants will receive a medication administration will be limited to before bedtime.
Study NCT05494203 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: questionnaire survey
Description: All patients received lifestyle questionnaire, medical history, physical signs, auxiliary examination and laboratory examination results before treatment.
Study NCT06073119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR441566
Description: Tablet
Study NCT05057728 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social-Emotional Prevention Program enhanced version
Description: The intervention is provided for all children for whom parental consent is obtained. The intervention includes a classroom curriculum, teacher training and parent training.
Study NCT06329388 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: TruHeight Growth Protein Shake
Description: Participants will be administered two scoops of TruHeight Growth Protein Shake, mixed with 12-16 fluid ounces of water, once daily, five times per week for six months. The supplement is intended to support growth patterns in children by providing essential nutrients that contribute to bone development and overall growth.
Study NCT05260411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered AK102 450 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
Study NCT05260411 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AK102
Description: Administered AK102 600 mg by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
Study NCT05260411 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered placebo by subcutaneous injection every 6 weeks Drug: Statins and/or Ezetimibe lipid-lowering therapies
Study NCT04776343 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemedecine follow-up
Description: weekly home-based follow-up of visual acuity on electronic tablet
Study NCT04914338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Health Promotion
Description: Participate in MDT-intervention
Study NCT04914338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04914338 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT05290870 — intervention group
Intervention type: DEVICE
Intervention: Posterior-chamber intraocular lens
Description: Implantation of a posterior-chamber intraocular lens to correct aphakia after removal of the crystalline lens
Study NCT06073119 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet
Study NCT06069778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT321 Dose Level 1
Description: Intravenous infusion
Study NCT06069778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT321 Dose Level 2
Description: Intravenous infusion
Study NCT06069778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFIRINOX
Description: Intravenous infusion
Study NCT06069778 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: mFOLFIRINOX
Description: Intravenous infusion
Study NCT06069778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BNT321 RP2D
Description: Intravenous infusion
Study NCT05134233 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity Focused Ultrasound
Description: LIFU application using various parameters, responses of neuromodulation recorded using TMS and EMG.
Study NCT05763563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Resistance Training
Description: Participants will be encouraged to perform approximately 30 minutes of resistance training exercises twice per week, until they undergo CART-T therapy. Exercises will be performed using resistance tubes (Bodylastics Resistance Bands Set) and a connectable bar (Bionic Body Workout Bar) that mimics a weighted barbell when tubes are attached. The tubes provide up to 142 pounds of resistance (adjustable in increments between 3-10 pounds) when simultaneously connected to handles or bar, and multiple tubes can be attached simultaneously.
Study NCT01220778 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Study NCT04244877 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin
Description: Drug: Rifaximin tablet
Study NCT03171545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Patient Activation
Description: Patients in clinics assigned to this group will be offered peer mentoring and digital resources.
Study NCT03171545 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Provider Education
Description: Staff in clinics assigned to this group will receive team training and a checklist.
Study NCT05232955 — intervention group
Intervention type: DEVICE
Intervention: PET/MR scanner
Description: Simultaneous PET and 3T MR scanning; protocol duration of approx. 100 min
Study NCT05343195 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Task-oriented exercise
Description: Task-oriented exercise program for patients after total hip replacement.
Study NCT04819009 — intervention group
Intervention type: OTHER
Intervention: the Enhanced Transtheoretical Model Intervention (ETMI)
Description: ETMI consists of a physical and functional examination, a discussion about the role of physical activity matched to the patient stage of change, and guided through motivational interviewing techniques, exposure to fast walking, and goal setting. The patient receives a postcard outlining the main messages about physical activity and four simple stretches.~The ETMI method consists of four parts:~1. Creating a therapeutic alliance (communication skills and reassurance)~2. Clear messages to the patient: Mandatory 3 sentences: (1. physical activity is the only thing that will help your back pain over time. 2. It's easy to reduce your pain now - but the important thing is to prevent the next episode, 3. Your body must be strong and flexible.)~3. Exposure to brisk walking (brisk walking in the corridor, hand by hand with the therapist) and graded activity.~4. Postcard with reminder messages on how to self manage the back.
Study NCT05343195 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Control intervention: conventional physiotherapy after hip replacement
Study NCT06464120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Increasing load strength training
Description: The Smith machine was used to intervene with athletes by employing an incremental load approach.
Study NCT06464120 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Constant load strength training
Description: The Smith machine was used to intervene with athletes by employing a constant load approach.
Study NCT05190835 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Optical scanner
Description: During the visits (Day 0 before surgery, Day 8, Day 21, Day 45, Month 3 and Month 6 after surgery), a measurement of the volume and the perimeter of the patient's two feet is carried out (operated foot and control foot). The edema is measured by a non-invasive method using an optical scanner (camera + laser scanning). The image processing software accompanying this tool has an automatic calculation of the volumes and the different perimeters of the foot. The measurement time by the scanner is less than 4 seconds.
Study NCT04702581 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PCV chemotherapy
Description: 1. cycle of PCV chemotherapy is given as:~   * Day 1: CCNU 110 mg/m2 orally;~  * Days 8 and 29: Vincristine 1.4 mg/m2 IV;~  * Days 8 to 21: Procarbazine 60 mg/m2 orally~6 cycles are given.
Study NCT04702581 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy and PCV chemotherapy
Description: Radiotherapy will deliver 50.4 Gy in 28 fractions of 1.8 Gy using IMRT technique.~Followed by 6 cycles of PCV chemotherapy~1 cycle of PCV is given as:~* Day 1: CCNU 110 mg/m2 orally;~* Days 8 and 29: Vincristine 1.4 mg/m2 IV;~* Days 8 to 21: Procarbazine 60 mg/m2 orally
Study NCT04696744 — intervention group
Intervention type: BIOLOGICAL
Intervention: CTC detection
Description: The collection and analysis of CTCs will be carried out in the following 6 steps: A blood sample will be taken: a maximum volume of 30 ml on 3 x 10 ml BD Vacutainer® EDTA tubes is required for the study.~CTCs will be enumerated and characterized by immunofluorescence after immunostaining with the following antibodies: anticytokeratin, anti-CD44, anti-N-cadherin and anti-PD-L1.~• - Secondary criterion(s) : Different tumor and clinical parameters will be analysed to find a correlation with CTC detection Gene expression profiles will be analyzed using the RNAseq single-cell at different times: before treatment, at interim times, and in case of relapse in order to establish correlations between patients at high risk of relapse and their molecular profiles
Study NCT05763563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: Participants will be encouraged to perform ≥30 minutes of moderate-intensity aerobic exercise on ≥3 days per week. Aerobic exercise intensity will be guided by heart rate zones, with participants exercising at 50-70% of their age-predicted maximum heart rate in bouts of at least 10 minutes at a time. Participants will be encouraged to gradually increase exercise intensity and duration until they are meeting the recommendation
Study NCT05763563 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Optional Aerobic Exercise Procedure
Description: Participants will be encouraged to complete 3 tele-supervised aerobic training sessions per week, each lasting 30 minutes. Participants will be encouraged to achieve moderate exercise intensity based on heart rate visualized on PM5 monitors. Participants will report their heart rates every 3-5 minutes during an exercise session and be encouraged to adjust pedaling cadence or flywheel resistance accordingly to achieve moderate intensity.~Exercise trainers will access logged heart rate ranges (64-76% of age-predicted maximum heart rate) to provide individualized and appropriate guidance during sessions.~Participants who are untrained or otherwise uncomfortable maintaining moderate aerobic intensity for 30 minutes will be encouraged to gradually increase the duration and intensity of their sessions until they are meeting these guidelines.
Study NCT05763563 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Optional In-Person Exercise Sessions
Description: Participants who prefer to complete RT and/or aerobic exercise sessions in-person will be allowed to do so. These sessions will be conducted in the Moffitt Promotes Resilience in Oncology Via Exercise (MPROVE) Laboratory using the same equipment participants would use for Zoom sessions, with guidance and supervision from certified exercise trainers.
Study NCT05502640 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education model
Description: Chicken legs will be used for each student in the study. Intermittent and continuous suture techniques will be studied on the incision made on the chicken leg.
Study NCT05502640 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Routine Education model
Description: In the study, 15 cm x 20 cm sponge will be used for each student. Intermittent and continuous suture techniques will be practiced on the sponge.
Study NCT04442529 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mothers and Babies (MB)
Description: Mothers and Babies is an evidence-based postpartum depression prevention intervention. It consists of 12 sessions which each last between 15-20 minutes. Intervention sessions are to be delivered either in person or by phone. The intervention is based on principles of cognitive-behavioral therapy (CBT).
Study NCT05071339 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ganirelix Acetate, Cetrolix Acetate
Description: 3-6 days of 0.25mg GnRH antagonist starting day 2-3 of the menstrual cycle prior to the administration of the original protocol.
Study NCT04112914 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Post-concussion education for families
Description: An educational intervention for families will be developed based on the CDC guidelines for returning to daily activities, school, and sports, adapted with stakeholder feedback to meet the learning needs of low health literacy parents.
Study NCT04896177 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sirolimus drug-eluting coronary balloon catheter
Description: Patients in experimental group will undergo PCI, using sirolimus drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
Study NCT04896177 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel drug-eluting coronary balloon catheter
Description: Patients in control group will undergo PCI, using paclitaxel drug-eluting coronary balloon catheter.Subjects without stent implantation were regularly treated with dual antiplatelet for 9 months after surgery. Subjects with stents were regularly treated with dual antiplatelet for 12 months after the surgery, in accordance with the applicable guidelines for percutaneous coronary intervention.
Study NCT06558890 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Alternating Current Stimulation
Description: Transcranial Alternating Current Stimulation
Study NCT06464211 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Model-Based Family Counseling Program
Description: A Cognitive Behavioral Model-Based Family Counseling Program is a therapeutic approach that focuses on identifying and changing negative thought patterns and behaviors within the family unit, using principles of cognitive-behavioral therapy to improve communication, resolve conflicts, and enhance overall family functioning.
Study NCT05355441 — intervention group
Intervention type: DRUG
Intervention: Paracetamol
Description: Routine clinical practice treatments recommended by the medical team involved
Study NCT05355441 — intervention group
Intervention type: DRUG
Intervention: Ibuprofen 600 mg
Description: Routine clinical practice treatments recommended by the medical team involved
Study NCT05355441 — intervention group
Intervention type: DRUG
Intervention: Tramadol
Description: Routine clinical practice treatments recommended by the medical team involved
Study NCT05355441 — intervention group
Intervention type: DRUG
Intervention: Morphine
Description: Routine clinical practice treatments recommended by the medical team involved
Study NCT04292600 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: POCKiT diagnostics' algorithm for LVO detection
Description: Measurement of blood biomarkers and integration within Pockit diagnostics' algorithm for LVO detection
Study NCT04932863 — intervention group
Intervention type: BIOLOGICAL
Intervention: BNT162b2 mRNA Covid-19 Vaccine
Description: Two injections, 21 days apart, of the BNT162b2 vaccine 30 μg per dose in the deltoid muscle.
Study NCT04675372 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: Dexmedetomidine group (Group D) was given 1.5ug/kg/h Dexmedetomidine continuous infusion
Study NCT04675372 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Midazolam
Description: Midazolam group (Group M) was continuously pumped with 0.05mg/kg/h midazolam
Study NCT05074472 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZB131
Description: ZB131 will be administered once weekly by intravenous infusion with the weight at baseline used for mg/kg dose calculations.
Study NCT05148273 — intervention group
Intervention type: BEHAVIORAL
Intervention: telenursing
Description: 7-24 counseling and daily treatment protocol reminders will be given to the intervention group.
Study NCT05824520 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ITS plus OMT
Description: Invasive treatment strategy plus optimal medical therapy
Study NCT05824520 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: OMT
Description: Optimal medical therapy alone
Study NCT05467943 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazemetostat
Description: All patients will receive 800 mg of Tazemetostat, BID, administered in continuous 28-day therapeutic cycle
Study NCT06162572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095018
Description: Via IV infusion on Day 1 of each 21-day cycle
Study NCT05282940 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Test Drug
Description: Investigational Medicinal Product
Study NCT05282940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Microgynon CD
Description: Microgynon CD will be used as a comparator drug for the BE study. Other Name: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Drug
Study NCT06162572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095024
Description: Via IV infusion on Day 1 of each 21-day cycle
Study NCT06162572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095029
Description: Via IV infusion on Day 1 of each 21-day cycle
Study NCT06162572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095018 Recommended Dose Expansion (RDE)
Description: Via IV infusion on Day 1 of each 21-day cycle
Study NCT06162572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095024 RDE
Description: Via IV infusion on Day 1 of each 21-day cycle
Study NCT06162572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S095029 RDE
Description: Via IV infusion on Day 1 of each 21-day cycle
Study NCT06162572 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cemiplimab
Description: 350 mg via IV infusion on Day 1 of each 21-day cycle
Study NCT06162572 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: 350 mg via IV infusion on Day 1 of each 21-day cycle
Study NCT06350318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib is an anti-cancer medication administered orally.
Study NCT06350318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Rituximab is a biologic medication administered intravenously or subcutaneously.
Study NCT04698330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine
Description: 0.6g (6 pills) of Berberine tablets administered twice a day orally before meal for 3 months
Study NCT04698330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inulin
Description: 0.6g (6 pills) of Inulin tablets administered twice a day orally before meal for 3 months
Study NCT04698330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Berberine placebo tablets
Description: 0.6g (6 pills) of Berberine placebo tablets administered twice a day orally before meal for 3 months
Study NCT04698330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Berberine placebo tablets
Description: 0.6g (6 pills) of Berberine placebo tablets administered twice a day orally before meal for 3 months
Study NCT04698330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inulin placebo tablets
Description: 0.6g (6 pills) of Inulin placebo tablets administered twice a day orally before meal for 3 months
Study NCT04698330 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Inulin placebo tablets
Description: 0.6g (6 pills) of Inulin placebo tablets administered twice a day orally before meal for 3 months
Study NCT05537129 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Total Gastrectomy
Description: The laparoscopic or open total gastrectomy with D2 lymphadenectomy was performed according to the Japanese gastric cancer treatment guidelines.
Study NCT05537129 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Gastrectomy
Description: The laparoscopic or open total gastrectomy with D2 lymphadenectomy was performed according to the Japanese gastric cancer treatment guidelines.
Study NCT05283850 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Calcium, Low Sodium (HCLS) Crystalloid Therapy
Description: Half-normal saline IV drip and 1g IV bolus Calcium Chloride.
Study NCT05283850 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: High Calcium, High Sodium (HCHS) Crystalloid Therapy
Description: Normal saline IV drip and 1g IV bolus Calcium Chloride.
Study NCT06229509 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Effective noninvasive ventilation
Description: Noninvasive ventilation set to alleviate dyspnea Inspiratory aid set according to a preliminary test (aiming for a diminution of 2 points in Borg score)
Study NCT06229509 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham noninvasive ventilation
Description: Noninvasive ventilation set with an insufficient inspiratory aid to alleviate dyspnea
Study NCT05195710 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Yttrium-90 (Y-90) resin microspheres
Description: Given by scan